Evolocumab, a monoclonal antibody that inhibits PCSK9, not only lowers LDL-C levels but also reduces the occurrence of major adverse cardiovascular events in individuals with established ASCVD, which includes prior MI, stroke, and peripheral vascular disease [88,89,90]. Here, PCSK9 is linked to atherosclerosis.